Cure Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology announced today that it has entered into a product development agreement with Therapix Biosciences Ltd. (Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments. The joint effort will formulate a proprietary cannabinoid-based product on CURE’s patented, multilayer oral thin film (OTF), CureFilm™, for the treatment of a wide range of sleep disorders.
This agreement is an extension of the recently announced partnership between CURE, Therapix and Israel’s Assuta Medical Centers, Ltd. to develop first-in-class therapeutic products in the fields of personalized medicine and cannabinoids.
Under terms of the product development agreement, CURE will develop a formulation that combines 2.5mg of dronabinol, a synthetic form of the key therapeutic cannabinoid endogenous to cannabis, 9-tetrahydrocannabinol (THC), and 200mg of palmitoylethanolamide (PEA) on its OTF technology. This formulation constitutes the advancement of Therapix’s clinical development program focusing on sleep disorders, as recently announced in the agreement between Therapix and Assuta Medical Center in the initiation of a Phase IIa clinical trial in obstructive sleep apnea.
Sleep apnea is a very large, underserved market with no available pharmaceutical treatments. An estimated 18 million patients suffer from this disorder in the U.S. The most common method of treatment uses a medical device called constant positive airway pressure (CPAP). While CPAP therapy can be effective in reducing sleep apnea, about half of patients on CPAP are non-adherent. This suggests a clear market need for a safe, effective pharmaceutical treatment for sleep apnea and other sleep disorders.
“We are enthusiastic about this next phase in our strategic partnership with Therapix. This product development agreement serves as testament that we are delivering on the goal we set forth when we first partnered in July to pool our expertise and resources to develop new products,” said CEO of CURE Rob Davidson. “Our main goal at CURE is to improve people’s lives by redefining how medications are delivered, and sleep disorders is a medical indication with high unmet need that I think we can significantly impact.”
Repurposing the FDA-approved dronabinol using Therapix’s proprietary combination that exhibits the “entourage effect” is key to improving patient compliance and reducing unwanted side-effects. Dr. Ascher Shmulewitz, Executive Chairman of Therapix, added, “Our goal at Therapix is to provide an optimized therapy for the treatment of a host of unmet medical needs, including sleep disorders, while reducing the dependence on more harmful drugs.”
Cure Pharmaceuticals has already completed the feasibility study for this new product and will begin proof of concept in the coming weeks, with the overall goal of providing a deeper un-interrupted sleep for the 40 million people who suffer from sleep related disorders in the United States. This, in addition to the way CURE’s CureFilm™ OTF technology offers a better option for the 40% of Americans who can’t swallow pills, improved bioavailability and fewer side effects, demonstrates CURE’s commitment to creating a world in which all people can take their medications easily and effectively.
Source: 420 Intel – United States